Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease [2]

Rheumatology

Volumn 44, Issue 2, 2005, Pages 256-257

  Moitra, R K ^a,b   Ledingham, J M ^a   Hull, R G ^a   McCrae, F C ^a   Thomas, A L ^a   Shaban, R ^a   MacKay, K R ^a  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; FOLIC ACID; METHOTREXATE;

ABDOMINAL PAIN; BODY WEIGHT DISORDER; CONTROLLED STUDY; DISEASE CONTROL; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALAISE; MEDICAL RECORD; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RHEUMATIC DISEASE; SELF INJECTION; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, PARENTERAL; METHOTREXATE; RHEUMATIC DISEASES;

EID: 14044272862     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh471     Document Type: Letter

References (5)

1. Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
2. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
3. Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology 2003;42:1009-10.
4. Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:91-4.
5. Mehta DK, ed. British National Formulary, Vol. 47. London: British Medical Association and Royal Pharmacological Society of Great Britain, 2004.